TY - JOUR T1 - A genetic model of ivabradine recapitulates results from randomized clinical trials JF - medRxiv DO - 10.1101/2020.01.29.20019521 SP - 2020.01.29.20019521 AU - Marc-André Legault AU - Johanna Sandoval AU - Sylvie Provost AU - Amina Barhdadi AU - Louis-Philippe Lemieux Perreault AU - Sonia Shah AU - R.Thomas Lumbers AU - Simon de Denus AU - Benoit Tyl AU - Jean-Claude Tardif AU - Marie-Pierre Dubé Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/02/03/2020.01.29.20019521.abstract N2 - Background Naturally occurring human genetic variants provide a valuable tool to identify drug targets and guide drug prioritization and clinical trial design. Ivabradine is a heart rate lowering drug with protective effects on heart failure despite increasing the risk of atrial fibrillation. In patients with coronary artery disease without heart failure, the drug does not protect against major cardiovascular adverse events prompting questions about the ability of genetics to have predicted those effects. This study evaluates the effect of a mutation in HCN4, ivabradine’s drug target, on safety and efficacy endpoints.Methods We used genetic association testing and Mendelian randomization to predict the effect of ivabradine and heart rate lowering on cardiovascular outcomes.Results Using data from the UK Biobank and large GWAS consortia, we evaluated the effect of a heart rate-reducing genetic variant at the HCN4 locus encoding ivabradine’s drug target. These genetic association analyses showed increases in risk for atrial fibrillation (OR 1.09, 95% CI: 1.06-1.13, P=9.3 ×10−9) in the UK Biobank. In a cause-specific competing risk model to account for the increased risk of atrial fibrillation, the HCN4 variant reduced incident heart failure in participants that did not develop atrial fibrillation (HR 0.90, 95% CI: 0.83-0.98, P=0.013). In contrast, the same heart rate reducing HCN4 variant did not prevent a composite endpoint of myocardial infarction or cardiovascular death (OR 0.99, 95% CI: 0.93-1.04, P=0.61).Conclusion Genetic modelling of ivabradine recapitulates its benefits in heart failure, promotion of atrial fibrillation, and neutral effect on myocardial infarction.CONDENSED ABSTRACT The effects of drugs can sometimes be predicted from the effects of mutations in genes encoding drug targets. We tested the effect of a heart rate reducing allele at the HCN4 locus encoding ivabradine’s drug target and found results coherent with the SHIFT and SIGNIFY clinical trials of ivabradine. The genetic variant increased the risk of atrial fibrillation and cardioembolic stroke and protected against heart failure in a competing risk model accounting for the increased risk of atrial fibrillation. The variant had a neutral effect on a composite of myocardial infarction and cardiovascular death.Competing Interest StatementA patent pertaining to pharmacogenomics-guided CETP inhibition was granted and J.-C.Tardif and M.-P. Dubé are mentioned as authors. J.-C.Tardif and M.-P. Dubé have a minor equity interest in DalCor. J.-C.Tardif has received research support from Amarin, AstraZeneca, DalCor, Eli-Lilly, Ionis, Pfizer, RegenexBio, Sanofi and Servier, and honoraria from DalCor, Pfizer, Sanofi and Servier. M.-P. Dubé has received honoraria from Dalcor and research support (access to samples and data) from AstraZeneca, Pfizer, Servier, Sanofi and GlaxoSmithKline. B. Tyl is an employee of Laboratoires Servier. Simon de Denus has received grants from Pfizer, AstraZeneca, Roche Molecular Science, DalCor and Novartis. R. Thomas Lumbers has received research grants from Pfizer. The remaining authors have nothing to disclose.Funding StatementThis work was supported by the Health Collaboration Acceleration Fund from the Ministère de l’Économie et de l’Innovation du Gouvernement du Québec. M.-A.L. is supported by a Frederick Banting and Charles Best Canada Graduate Scholarship Doctoral Award from the Canadian Institutes of Health Research (CIHR). J.-C.T. holds the Canada Research Chair in personalized medicine and the Université de Montréal Pfizer-endowed research chair in atherosclerosis. S. d.D. holds the Université de Montréal Beaulieu-saucier Chair in Pharmacogenomics. SS is partly supported by a National Health and Medical Research Council (NHMRC) fellowship and NHMRC Program Grant 1113400. R.T.L. is supported by a UK Research and Innovation Rutherford Fellowship.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnalyses in this manuscript are based on publicly available GWAS summary statistics or individual-level data from the UK Biobank. The UK Biobank resource is available for health researchers to conduct health-related research that is in the public's interest. Access to the resource and the approval process is managed by the UK Biobank (https://www.ukbiobank.ac.uk/researchers/).BPMBeats per minuteMRMendelian RandomizationSHIFTSystolic Heart failure treatment with the If inhibitor ivabradine TrialSIGNIFYStudy Assessing the Morbidity–Mortality Benefits of the If Inhibitor Ivabradine in Patients with Coronary Artery DiseaseOROdds RatioHRHazard RatioCIConfidence intervalCADCoronary Artery DiseaseGWASGenome-Wide Association StudyGRSGenetic Risk Score ER -